Article
Cardiac & Cardiovascular Systems
Chiara Lestuzzi, Maurizio Mascarin, Elisa Coassin, Maria Laura Canale, Fabio Turazza
Summary: Radiotherapy may lead to various heart diseases, including valvular heart disease, coronary artery disease, and left ventricular dysfunction. Interventional therapy is more common in symptomatic patients at the time of RIHD diagnosis. Clinically relevant RIHD may occur approximately 16 years after radiotherapy.
FRONTIERS IN CARDIOVASCULAR MEDICINE
(2021)
Article
Endocrinology & Metabolism
S. Abdelgani, C. Puckett, J. Adams, C. Triplitt, R. A. DeFronzo, M. Abdul-Ghani
Summary: The study demonstrated that beta cell function plays a vital role in predicting response to glucose lowering medications in newly diagnosed T2DM patients. The C-Pep(120)/C-Pep(0) ratio is a practical tool for guiding the choice of glucose lowering agent.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2021)
Review
Cell Biology
Joseph Nowell, Eleanor Blunt, Dhruv Gupta, Paul Edison
Summary: Therapeutic strategies for neurodegenerative disorders have had limited success by targeting individual aspects of the disease pathogenesis. However, a link between Alzheimer's disease (AD)/Parkinson's disease (PD) and type 2 diabetes mellitus has opened up a promising avenue for repurposing antidiabetic agents in the treatment of these disorders. Targeting cerebral insulin signalling and brain incretin receptors have shown potential in preclinical and clinical studies, with approved diabetic compounds improving motor symptoms of PD and preventing neurodegenerative decline. Additional approved diabetic treatments are also being investigated for deployment in PD and AD treatment. This comprehensive review explores several promising antidiabetic agents for the treatment of AD and PD.
AGEING RESEARCH REVIEWS
(2023)
Article
Cardiac & Cardiovascular Systems
Pascal M. Burger, Stefan Koudstaal, Jannick A. N. Dorresteijn, Gianluigi Savarese, Manon G. van der Meer, Gert J. de Borst, Arend Mosterd, Frank L. J. Visseren
Summary: This study found that metabolic syndrome and insulin resistance are associated with an increased risk of incident heart failure in non-diabetic patients with established cardiovascular disease. Specifically, higher waist circumference independently increases the risk of heart failure. These findings highlight the importance of managing metabolic syndrome and insulin resistance in cardiovascular disease patients.
INTERNATIONAL JOURNAL OF CARDIOLOGY
(2023)
Review
Endocrinology & Metabolism
Wei-Ren Lin, Kuan-Hung Liu, Tsai-Chieh Ling, Ming-Cheng Wang, Wei-Hung Lin
Summary: Insulin resistance is a condition where target tissues have a diminished response to insulin, resulting in impaired glucose uptake and elevated blood sugar levels. This can lead to beta cell dysfunction and ultimately the development of type 2 diabetes mellitus. Insulin resistance is also associated with cardiovascular disease and is common in patients with chronic kidney disease. The mechanisms of insulin resistance in CKD are complex and include factors such as physical inactivity, inflammation, metabolic acidosis, and vitamin D deficiency. Various anti-diabetic medications have different effects on insulin resistance. This review discusses the potential mechanisms of insulin resistance in CKD patients and the interaction of current anti-diabetic medications with insulin resistance.
WORLD JOURNAL OF DIABETES
(2023)
Article
Cardiac & Cardiovascular Systems
Deewa Zahir, Anders Bonde, Christian Madelaire, Morten Malmborg, Jawad H. Butt, Emil Fosbol, Gunnar Gislason, Christian Torp-Pedersen, Charlotte Andersson, Patrick Rossignol, John J. McMurray, Lars Kober, Morten Schou
Summary: This study investigated the temporal trends in the initiation, withdrawal, and adherence of mineralocorticoid receptor antagonists (MRA) in heart failure (HF) patients in Denmark. The findings revealed that approximately half of the patients initiated MRA therapy within 6 months after diagnosis, but approximately half of them withdrew from MRA treatment within 5 years. These findings underscore the importance of focusing on the retention of MRA treatment in real-life clinical practice.
EUROPEAN JOURNAL OF HEART FAILURE
(2022)
Review
Medicine, General & Internal
Lorenzo Pistelli, Francesca Parisi, Michele Correale, Federica Cocuzza, Francesca Campanella, Tommaso de Ferrari, Pasquale Crea, Rosalba De Sarro, Olga La Cognata, Simona Ceratti, Tonino Recupero, Gaetano Ruocco, Alberto Palazzuoli, Egidio Imbalzano, Giuseppe Dattilo
Summary: Heart failure is a complex condition affecting millions of people worldwide, with significant impacts on morbidity, mortality, and healthcare costs. Over the past 50 years, numerous therapeutic options have been developed based on a better understanding of the underlying pathophysiology. The recent inclusion of sodium-glucose cotransporter inhibitors as first-line therapy for heart failure with reduced ejection fraction in the European Society of Cardiology guidelines highlights the potential benefits of these drugs in reducing hospitalizations and mortality.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Medicine, General & Internal
Marta Carrillo-Palau, Alejandro Hernandez-Camba, Noemi Hernandez Alvarez-Buylla, Laura Ramos, Inmaculada Alonso-Abreu, Anjara Hernandez-Perez, Milagros Vela, Laura Arranz, Manuel Hernandez-Guerra, Miguel A. Gonzalez-Gay, Ivan Ferraz-Amaro
Summary: This study found that insulin resistance (IR) is not increased in inflammatory bowel disease (IBD) patients with low disease activity compared to controls. However, the presence of nonalcoholic fatty liver disease (NAFLD) favors the development of IR in patients with IBD.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Medicine, General & Internal
Yaar S. Aga, Sumant P. Radhoe, Dilan Aydin, G. C. M. Linssen, Philip C. Rademaker, Peter R. Geerlings, Marco W. F. van Gent, Ismail Aksoy, Liane Oosterom, Hans-Peter Brunner-La Rocca, Bas M. van Dalen, Jasper J. Brugts
Summary: This study aimed to evaluate heart failure treatment in a large real-world Western European cohort with and without obesity. The results showed that obese patients were more frequently prescribed guideline-recommended medications at higher doses.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION
(2023)
Review
Cell Biology
Desh Deepak Singh, Ali A. Shati, Mohammad Y. Alfaifi, Serag Eldin I. Elbehairi, Ihn Han, Eun-Ha Choi, Dharmendra K. Yadav
Summary: There are common molecular mechanisms and underlying pathology, such as insulin resistance and impaired synaptic plasticity, between type 2 diabetes mellitus and dementia. Analyzing risk factors is crucial for disease development and clinical management.
Article
Medicine, General & Internal
Nadia Aspromonte, Luigi Cappannoli, Pietro Scicchitano, Francesco Massari, Ivan Pantano, Massimo Massetti, Filippo Crea, Roberto Valle
Summary: The study found that low pre-discharge BNP levels were associated with low rates of cardiovascular events in HF patients, independently of the frequency of follow-up. Additionally, age, creatinine, and BNP were identified as independent predictors of events in HF patients.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Cardiac & Cardiovascular Systems
Lorenzo Rampa, Roberto Santangelo, Carlo Gaspardone, Alice Cerutti, Giuseppe Magnani, Francesco Piscazzi, Giulia Sgherzi, Giorgio Fiore, Massimo Filippi, Federica Agosta, Alberto Margonato, Gabriele Fragasso
Summary: AChE-I treatment in patients with dementia may reduce the risk of cardiovascular events, particularly heart failure and myocardial revascularization. The use of AChE-I in dementia patients may be protective for cardiovascular outcomes.
AMERICAN JOURNAL OF CARDIOLOGY
(2023)
Article
Cardiac & Cardiovascular Systems
Juntao Tan, Yuxin He, Zhanbiao Li, Xiaomei Xu, Qinghua Zhang, Qian Xu, Lingqin Zhang, Shoushu Xiang, Xuewen Tang, Wenlong Zhao
Summary: This study established and validated a non-invasive diagnostic nomogram to identify heart failure in patients with coronary heart disease. The nomogram included factors such as age, hypertension, and various laboratory levels, and demonstrated good predictive accuracy and clinical value in both internal and external validation sets.
FRONTIERS IN CARDIOVASCULAR MEDICINE
(2022)
Review
Pharmacology & Pharmacy
Braydon Hall, Michel Rapinski, Danielle Spoor, Hoda Eid, Ammar Saleem, John T. Arnason, Brian Foster, Alain Cuerrier, Pierre S. Haddad, Cory S. Harris
Summary: An ethnopharmacological metanalysis was conducted to determine the traditional knowledge of indigenous Cree in James Bay, Canada, about the antidiabetic activities of plant foods and medicines from the northern boreal forest. The study found that certain plants showed high pharmacological importance in primary, secondary, and safety bioassays, and the pharmacological variability was better described by plant biology.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Cardiac & Cardiovascular Systems
Jasper Tromp, Wouter Ouwerkerk, John G. F. Cleland, Christiane E. Angermann, Ulf Dahlstrom, Katherine Tiew-Hwa Teng, Sahiddah Bamadhaj, Georg Ertl, Mahmoud Hassanein, Sergio Perrone, Mathieu Ghadanfar, Anja Schweizer, Achim Obergfell, Gerasimos Filippatos, Sean P. Collins, Carolyn S. P. Lam, Kenneth Dickstein
Summary: This study investigated global differences in prevalence, association with outcome, and treatment of ischemic heart disease (IHD) in patients with acute heart failure (AHF). It found that IHD was more common in low-income countries and was associated with higher 1-year mortality, especially in patients with heart failure with reduced ejection fraction (HFrEF). Patients in regions with the greatest burden of IHD were less likely to receive coronary revascularization and treatment for IHD.
JACC-HEART FAILURE
(2021)
Review
Cardiac & Cardiovascular Systems
Enrique Z. Fisman, Alexander Tenenbaum
CARDIOVASCULAR DIABETOLOGY
(2015)
Article
Cardiac & Cardiovascular Systems
Robert Klempfner, Avishay Elis, Shlomi Matezky, Gad Keren, Arie Roth, Ariel Finkelstein, Shmuel Banai, Ilan Goldenberg, Enrique Z. Fisman, Alexander Tenenbaum, Yaron Arbel
INTERNATIONAL JOURNAL OF CARDIOLOGY
(2015)
Article
Cardiac & Cardiovascular Systems
Robert Klempfner, Ilan Goldenberg, Enrique Z. Fisman, Shlomi Matetzky, Uri Amit, Joseph Shemesh, Alexander Tenenbaum
AMERICAN JOURNAL OF CARDIOLOGY
(2014)
Review
Cardiac & Cardiovascular Systems
Alexander Tenenbaum, Enrique Z. Fisman
CARDIOLOGY JOURNAL
(2013)
Review
Cardiac & Cardiovascular Systems
Enrique Z. Fisman, Alexander Tenenbaum
CARDIOLOGY JOURNAL
(2014)
Letter
Cardiac & Cardiovascular Systems
Enrique Z. Fisman, Alexander Tenenbaum
CARDIOLOGY JOURNAL
(2014)
Article
Cardiac & Cardiovascular Systems
Robert Klempfner, Ilan Goldenberg, Enrique Z. Fisman, Uri Amit, Alexander Haitovich, Shlomi Matetzky, Diego Medvedofsky, Joseph Shemesh, Alexander Tenenbaum
CARDIOLOGY JOURNAL
(2014)
Review
Cardiac & Cardiovascular Systems
Alexander Tenenbaum, Enrique Z. Fisman
CARDIOVASCULAR DIABETOLOGY
(2012)
Review
Cardiac & Cardiovascular Systems
Alexander Tenenbaum, Enrique Z. Fisman
CARDIOVASCULAR DIABETOLOGY
(2012)
Article
Cardiac & Cardiovascular Systems
Joseph Shemesh, Alexander Tenenbaum, Enrique Z. Fisman, Nira Koren-Morag, Ehud Grossman
CARDIOVASCULAR DIABETOLOGY
(2013)
Review
Cardiac & Cardiovascular Systems
Enrique Z. Fisman, Alexander Tenenbaum
CARDIOVASCULAR DIABETOLOGY
(2014)
Editorial Material
Cardiac & Cardiovascular Systems
Alexander Tenenbaum, Enrique Z. Fisman
CARDIOVASCULAR DIABETOLOGY
(2018)
Letter
Cardiac & Cardiovascular Systems
Alexander Tenenbaum, Enrique Z. Fisman, Joseph Shemesh, Michael Motro
INTERNATIONAL JOURNAL OF CARDIOLOGY
(2011)
Article
Multidisciplinary Sciences
Alexander Tenenbaum, Diego Medvedofsky, Enrique Z. Fisman, Liudmila Bubyr, Shlomi Matetzky, David Tanne, Robert Klempfner, Joseph Shemesh, Ilan Goldenberg
Editorial Material
Cardiac & Cardiovascular Systems
Enrique Z. Fisman, Alexander Tenenbaum
Summary: Incretin hormones, including GLP-1 and GIP, play a crucial role in the treatment of type 2 diabetes. While GIP was previously considered an unappealing therapeutic target, recent studies have shown that its effectiveness can be restored. Novel dual GIP and GLP-1 receptor agonists like tirzepatide present promising advancements in lowering glucose levels and improving metabolic profiles.
CARDIOVASCULAR DIABETOLOGY
(2021)